Olmesartan/amlodipine

Olmesartan/amlodipine, sold under the brand name Azor, among others is a combination medication used to treat high blood pressure. It combines two antihypertensive agents in a film-coated tablet. It contains amlodipine, a calcium channel blocker, and olmesartan medoxomil, an angiotensin-2 receptor antagonist (ARB or A2A). The patent is held by Daiichi Sankyo Pharmaceuticals. Daiichi Sankyo filed a supplemental New Drug Application (sNDA) for Azor with the United States Food and Drug Administration on September 17, 2008.[1] Azor has been studied in clinical trials; one test showed it reduced blood pressure during a 24-hour period and was well tolerated.[2]

Olmesartan/amlodipine
Combination of
OlmesartanAngiotensin II antagonist
AmlodipineCalcium channel blocker
Clinical data
Trade namesAzor
AHFS/Drugs.comazor
Pregnancy
category
  • US: D (Evidence of risk)
    Routes of
    administration    		Oral
    ATC code
    Legal status
    Legal status

    Preparations

    Azor is available in different dose preparations: 5 mg/20 mg, 10 mg/20 mg,5 mg/40 mg and 10/40 mg's of amlodipine and olmesartan respectively.[3] One investigation (which included doctors employed by Daiichi Sankyo) concluded that "From a pharmacokinetic perspective, the 2 drugs (amlodipine and olmesartan) are well suited to coadministration in a fixed-dose combination."[4]

    References
    1. PR Newswire (Sep 17, 2008). "Daiichi Sankyo, Inc. Files Supplemental New Drug Application for AZOR(R) as Initial..." Reuters. Retrieved 2009-10-06.
    2. Joel M Neutel, MD & Henry Punzi, MD (June 2009). "The AZTEC Trial: Amlodipine Besylate/Olmesartan Medoxomil (Azor)". P T. Pharmacy & Therapeutics. 34 (6): 318–21. PMC 2697919. PMID 19572050.
    3. Daiichi Sankyo, Inc (2009-10-06). "Information about Azor from the manufacturer". Daiichi Sankyo, Inc. Archived from the original on 29 September 2009. Retrieved 2009-10-06.
    4. Shashank Rohatagi, James Lee, Magdy Shenouda, MD, Stephen Haworth, MD, Mohinder Singh Bathala, Mark Allison, MD, Igor Rubets, Reinilde Heyrman, MD, Robert Noveck, MD and Daniel E. Salazar, FCP (2009-10-06). "PHARMACOKINETICS -- Pharmacokinetics of Amlodipine and Olmesartan After Administration of Amlodipine Besylate and Olmesartan Medoxomil in Separate Dosage Forms and as a Fixed-Dose Combination". The Journal of Clinical Pharmacology. Retrieved 2009-10-06.CS1 maint: multiple names: authors list (link)


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.